Vertex Pharmaceuticals Inc. buy stratec
Start price
14.01.18
/
50%
€142.77
Target price
11.01.19
€170.18
Performance (%)
18.71%
End price
11.01.19
€169.48
Summary
This prediction ended on 11.01.19 with a price of €169.48. The BUY prediction by stratec finished with a performance of 18.71%. stratec has a follow-up prediction for Vertex Pharmaceuticals Inc. where he still thinks Vertex Pharmaceuticals Inc. is a Buy. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Vertex Pharmaceuticals Inc. | 3.370% | 3.370% | -0.250% | 46.707% |
| iShares Core DAX® | 3.002% | 3.742% | 24.169% | 65.664% |
| iShares Nasdaq 100 | 2.966% | 1.308% | 9.141% | 111.170% |
| iShares Nikkei 225® | 5.606% | 4.472% | 21.237% | 55.883% |
| iShares S&P 500 | 2.312% | 1.880% | 6.333% | 67.956% |
Comments by stratec for this prediction
In the thread Vertex Pharmaceuticals Inc. diskutieren
Vertex wins expanded approval for its cystic fibrosis combo
Looking forward: VRTX moves the needle here with this approval. Now, it would appear as though the European approval matches that in America, and this can be a good tool for young patients with this form of cystic fibrosis. The $250,000+ price tag on Orkambi means that even with only reaching a third of the patients, the company stands to gain hundreds of millions in revenue a year from this.
stratec stimmt am 14.01.2018 der Outperform-Einschätzung der institutionellen Analysten aber mit dem Kursziel 188,67$ zu.
(Vom Mitglied beendet)
Current prediction by stratec for Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€414.00
09.04.25
09.04.25
€480.00
09.04.26
09.04.26
-3.68%
09.01.26
09.01.26
